4.5 Article

Irreversible modifications of receptor tyrosine kinases

Journal

FEBS LETTERS
Volume 592, Issue 13, Pages 2199-2212

Publisher

WILEY
DOI: 10.1002/1873-3468.13095

Keywords

ectodomain shedding; receptor proteolysis; receptor tyrosine kinases

Ask authors/readers for more resources

Each group of the 56 receptor tyrosine kinases (RTK) binds with one or more soluble growth factors and coordinates a vast array of cellular functions. These outcomes are tightly regulated by inducible post-translational events. such as tyrosine phosphorylation, ubiquitination, ectodomain shedding, and regulated intramembrane proteolysis. Because of the delicate balance required for appropriate RTK function, cells may become pathogenic upon dysregulation of RTKs themselves or their post-translational covalent modifications. For example, reduced ectodomain shedding and decreased ubiquitination of the cytoplasmic region, both of which enhance growth factor signals. characterize malignant cells. Whereas receptor phosphorylation and ubiquitination are reversible, proteolytic cleavage events are irreversible, and either modification might alter the subcellular localization of RTKs. Herein, we focus on ectodomain shedding by metalloproteinases (including ADAM family proteases), cleavage within the membrane or cytoplasmic regions of RTKs (by gamma-secretases and caspases, respectively), and complete receptor proteolysis in lysosomes and proteasomes. Roles of irreversible modifications in RTK signaling, pathogenesis, and pharmacology are highlighted.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer

Samatha Bhat, Shama Prasada Kabekkodu, Ashish Noronha, Kapaettu Satyamoorthy

BIOCHIMIE (2016)

Article Oncology

A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways

Donatella Romaniello, Luigi Mazzeo, Maicol Mancini, Ilaria Marrocco, Ashish Noronha, Matthew Kreitman, Swati Srivastava, Soma Ghosh, Moshit Lindzen, Tomer Meir Salame, Amir Onn, Jair Bar, Yosef Yarden

CLINICAL CANCER RESEARCH (2018)

Article Biochemistry & Molecular Biology

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors

Lee Roth, Swati Srivastava, Moshit Lindzen, Aldema Sas-Chen, Michal Sheffer, Mattia Lauriola, Yehoshua Enuka, Ashish Noronha, Maicol Mancini, Sara Lavi, Gabi Tarcic, Gur Pines, Nava Nevo, Ori Heyman, Tamar Ziv, Oscar M. Rueda, Davide Gnocchi, Eli Pikarski, Arie Admon, Carlos Caldas, Yosef Yarden

SCIENCE SIGNALING (2018)

Article Biochemistry & Molecular Biology

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors

Lee Roth, Swati Srivastava, Moshit Lindzen, Aldema Sas-Chen, Michal Sheffer, Mattia Lauriola, Yehoshua Enuka, Ashish Noronha, Maicol Mancini, Sara Lavi, Gabi Tarcic, Gur Pines, Nava Nevo, Ori Heyman, Tamar Ziv, Oscar M. Rueda, Davide Gnocchi, Eli Pikarski, Arie Admon, Carlos Caldas, Yosef Yarden

SCIENCE SIGNALING (2018)

Article Biochemistry & Molecular Biology

Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies

Ruth Maron, Bilha Schechter, Nishanth Belugali Nataraj, Soma Ghosh, Donatella Romaniello, Ilaria Marrocco, Ashish Noronha, Silvia Carvalho, Yosef Yarden, Michael Sela

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)

Article Oncology

Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer

Simone Borgoni, Emre Sofyali, Maryam Soleimani, Heike Wilhelm, Karin Mueller-Decker, Rainer Will, Ashish Noronha, Lukas Beumers, Pernette J. Verschure, Yosef Yarden, Luca Magnani, Antoine H. C. van Kampen, Perry D. Moerland, Stefan Wiemann

CANCERS (2020)

Article Oncology

Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors

Yuya Haga, Ilaria Marrocco, Ashish Noronha, Mary Luz Uribe, Nishanth Belugali Nataraj, Arunachalam Sekar, Diana Drago-Garcia, Simone Borgoni, Moshit Lindzen, Suvendu Giri, Stefan Wiemann, Yasuo Tsutsumi, Yosef Yarden

Summary: This study reveals an unconventional mechanism of resistance to dacomitinib in lung cancer cells and uncovers a previously unknown step of resistance acquisition. The resistant cells did not acquire secondary mutations in EGFR but displayed characteristics of epithelial-mesenchymal transition. Interestingly, when implanted in animals, the resistant cells reverted to a dacomitinib-sensitive state, but regained resistance when cultured in vitro.

CANCER RESEARCH (2021)

Article Biochemistry & Molecular Biology

Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53

Moshit Lindzen, Soma Ghosh, Ashish Noronha, Diana Drago, Nishanth Belugali Nataraj, Orith Leitner, Silvia Carvalho, Einav Zmora, Stav Sapoznik, Keren Bahar Shany, Keren Levanon, Dan Aderka, Belinda Sanchez Ramirez, Maik Dahlhoff, Iain McNeish, Yosef Yarden

Summary: Research suggests that AREG is overexpressed in abdominal fluids of ovarian cancer patients, and its immune modulation is associated with animal survival. The generation of a new antibody to target AREG has extended the survival time of mice.

ONCOGENE (2021)

Article Biochemistry & Molecular Biology

Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma

Anamika Singh, Ariel Erijman, Ashish Noronha, Hemant Kumar, Yoav Peleg, Yosef Yarden, Julia M. Shifman

Summary: The study demonstrates that engineered RASSF5 variants can inhibit Ras-regulated procancer pathways and stimulate anticancer processes, providing an attractive therapeutic strategy against cancer development.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

Article Cell Biology

Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors

Nishanth Belugali Nataraj, Ashish Noronha, Joo Sang Lee, Soma Ghosh, Harsha Raj Mohan Raju, Arunachalam Sekar, Binyamin Zuckerman, Moshit Lindzen, Emilio Tarcitano, Swati Srivastava, Michael Selitrennik, Ido Livneh, Diana Drago-Garcia, Oscar Rueda, Carlos Caldas, Sima Lev, Tamar Geiger, Aaron Ciechanover, Igor Ulitsky, Rony Seger, Eytan Ruppin, Yosef Yarden

Summary: By establishing multi-omics pipelines, we discovered that overexpression of NUP93 is associated with aggressive human mammary tumors, enhancing their migration and invasion capabilities. NUP93 is involved in nuclear transport, activating various signaling pathways and ultimately contributing to tumor growth and metastasis. Targeting this nuclear transport process with myristoylated peptides can inhibit tumor growth and metastasis.

CELL REPORTS (2022)

Article Oncology

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

Ashish Noronha, Nishanth Belugali Nataraj, Joo Sang Lee, Benny Zhitomirsky, Yaara Oren, Sara Oster, Moshit Lindzen, Saptaparna Mukherjee, Rainer Will, Soma Ghosh, Arturo Simoni-Nieves, Aakanksha Verma, Rishita Chatterjee, Simone Borgoni, Welles Robinson, Sanju Sinha, Alexander Brandis, D. Lucas Kerr, Wei Wu, Arunachalam Sekar, Suvendu Giri, Youngmin Chung, Diana Drago-Garcia, Brian P. Danysh, Mattia Lauriola, Michelangelo Fiorentino, Andrea Ardizzoni, Moshe Oren, Collin M. Blakely, Jideofor Ezike, Stefan Wiemann, Laxmi Parida, Trever G. Bivona, Rami Aqeilan, Joan S. Brugge, Aviv Regev, Gad Getz, Eytan Ruppin, Yosef Yarden

Summary: EGFR inhibitors activate endogenous mutators in lung cancer cells, leading to drug resistance. Inhibiting this process can prevent drug resistance.

CANCER DISCOVERY (2022)

Article Cell Biology

PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR

Soma Ghosh, Nishanth Belugali Nataraj, Ashish Noronha, Sushant Patkar, Arunachalam Sekar, Saptapama Mukherjee, Sabina Winograd-Katz, Lior Kramarski, Aakanksha Verma, Moshit Lindzen, Diana Drago Garcia, Joseph Green, Galit Eisenberg, Hava Gil-Henn, Arkaprabha Basu, Yan Lender, Shimon Weiss, Moshe Oren, Michal Lotem, Benjamin Geiger, Eytan Ruppin, Yosef Yarden

Summary: The research indicates that tumors with EGFR mutations have a lower response to immunotherapy, the EGFR pathway is associated with high PD-L1 expression and can promote an aggressive phenotype, while anti-PD-L1 antibodies can inhibit PD-L1 functions.

CELL REPORTS (2021)

Article Medicine, Research & Experimental

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors

Maicol Mancini, Hilah Gal, Nadege Gaborit, Luigi Mazzeo, Donatella Romaniello, Tomer Meir Salame, Moshit Lindzen, Georg Mahlknecht, Yehoshua Enuka, Dominick G. A. Burton, Lee Roth, Ashish Noronha, Ilaria Marrocco, Dan Adreka, Raya Eilam Altstadter, Emilie Bousquet, Julian Downward, Antonio Maraver, Valery Krizhanovsky, Yosef Yarden

EMBO MOLECULAR MEDICINE (2018)

No Data Available